News
HNSBF
2.900
NaN%
--
Hansa Biopharma CEO to Join Industry Panel at Biotech in Europe Forum
TipRanks · 3d ago
Hansa Biopharma Taps Cradle’s AI Platform to Speed Autoimmune Drug Discovery
TipRanks · 4d ago
Hansa Biopharma Adds Commercial and Financial Heavyweights to Board
TipRanks · 09/24 05:33
Hansa Biopharma Adds New Directors and Adopts Long-Term RSU Program at Extraordinary Meeting
TipRanks · 09/22 16:02
Hansa Biopharma Joins Global Expansion Panel at LSX Congress USA
TipRanks · 09/21 15:32
Hansa Biopharma Calls Extraordinary Meeting to Reshape Board and Governance
TipRanks · 08/21 06:02
Hansa Biopharma Prepares for Potential U.S. ADS Listing and Global Share Offering
TipRanks · 08/21 05:32
Hansa Biopharma Marks First Commercial Idefirix Kidney Transplant in Australia
TipRanks · 08/18 06:33
Douglas Tsao Reiterates Buy on Hansa, Maintains $103 Price Target Amid Strategic Pivot and Operational Recovery
TipRanks · 07/23 15:25
Hansa Biopharma Bets Big On U.S. Kidney Launch
TipRanks · 07/23 00:12
Hansa Biopharma GAAP EPS of SEK -2.56, revenue of SEK 48.1M
Seeking Alpha · 07/22 16:55
Hansa Biopharma bolsters finances with €115m Idefirix deal as clinical data strengthen transplant outlook
TipRanks · 07/22 05:33
Empire State Realty signs Instacart office lease; lifts 111 W. 33rd Street to 100% occupancy
Seeking Alpha · 07/20 21:46
Hansa Biopharma sets Q2 2026 results release and investor call
TipRanks · 07/08 10:02
Hansa Biopharma to Highlight Kidney Desensitization Technology at Wedbush PacGrow Renal Summit
TipRanks · 07/02 11:32
Hansa Biopharma seals €115m Idefirix licensing deal with SERB
TipRanks · 07/01 13:03
Hansa Biopharma: Buy Rating Reiterated as Imlifidase Growth Opportunity Widens; Price Target Maintained at SEK103
TipRanks · 06/29 10:15
Hansa Biopharma’s Phase 3 Kidney Transplant Data Earns Prime Spot at ATC 2026
TipRanks · 06/24 21:03
Hansa Biopharma initiated with a Buy at Danske Bank
TipRanks · 06/16 09:30
Hansa Biopharma Names Veteran Biotech Executive Adam Cutler as New CFO
TipRanks · 06/15 05:35
More
Webull provides a variety of real-time HNSBF stock news. You can receive the latest news about Hansa Medical AB through multiple platforms. This information may help you make smarter investment decisions.
About HNSBF
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.